Ibrutinib-d5 – 1 mg

Brand:
Cayman
CAS:
1553977-17-5
Storage:
-20
UN-No:
Non-Hazardous - /

Ibrutinib-d5 is intended for use as an internal standard for the quantification of ibrutinib (Item No. 16274) by GC- or LC-MS. Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent).{27081,27080} It has been reported to inhibit autophosphorylation of BTK (IC50 = 11 nM), phosphorylation of PLCγ (IC50 = 29 nM), a substrate of BTK, and phosphorylation of ERK (IC50 = 13 nM), a further downstream kinase.{27081} Formulations containing it have been examined clinically for the treatment of diseases associated with B cell antigen receptor signaling, including mantle cell lymphoma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.{24859,27081,24780}  

 

Out of stock

SKU: 22561 - Category:

Description

An internal standard for the quantification of ibrutinib by GC- or LC-MS,


Formal name: 1-[(3R)-3-[4-amino-3-[4-(phenoxy-2,3,4,5,6-d5)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one

Synonyms: 

Molecular weight: 445.5

CAS: 1553977-17-5

Purity: ≥99% deuterated forms (d1-d5)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|Tec Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Tec Family Signaling||Research Area|Cancer|Tumor Microenvironment||Research Area|Immunology & Inflammation|Adaptive Immunity